Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:3699052rdf:typepubmed:Citationlld:pubmed
pubmed-article:3699052lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:3699052lifeskim:mentionsumls-concept:C0018792lld:lifeskim
pubmed-article:3699052lifeskim:mentionsumls-concept:C0001888lld:lifeskim
pubmed-article:3699052lifeskim:mentionsumls-concept:C0235169lld:lifeskim
pubmed-article:3699052lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:3699052lifeskim:mentionsumls-concept:C0348016lld:lifeskim
pubmed-article:3699052lifeskim:mentionsumls-concept:C0457405lld:lifeskim
pubmed-article:3699052pubmed:issue2lld:pubmed
pubmed-article:3699052pubmed:dateCreated1986-6-12lld:pubmed
pubmed-article:3699052pubmed:abstractTextSlow conduction of early extrastimuli and short refractory periods are some of the factors underlying atrial fibrillation in man. In order to study the effect of ajmaline, a class I antiarrhythmic agent, on these variables, we have performed electrophysiologic studies in 13 patients with and without atrial arrhythmias, before and after the intravenous administration of 1 mg kg-1 of ajmaline chlorhydrate. During paced rhythm with a 600 ms cycle length, extrastimuli were applied to the right atrial appendage, and conduction to the low septal right atrium and the coronary sinus were measured. Ajmaline prolonged P wave duration from 111 +/- 15 to 140 +/- 24 ms (P less than 0.001), conduction of baseline stimuli to low septal right atrium from 69 +/- 14 to 95 +/- 21 ms (P less than 0.001) and to coronary sinus from 127 +/- 18 to 165 +/- 29 ms (P less than 0.001). Atrial effective refractory period increased from 207 +/- 23 to 255 +/- 27 ms (P less than 0.001). Maximum conduction delay of early extrastimuli decreased at the low septal right atrium from 43 +/- 22 to 29 +/- 16 ms (P less than 0.25) and at the coronary sinus from 47 +/- 22 to 21 +/- 14 ms (P less than 0.001). These results show interesting electrophysiologic effects of ajmaline on atrial tissue, with reversion of some of the abnormalities underlying atrial fibrillation, and suggest an antiarrhythmic effect.lld:pubmed
pubmed-article:3699052pubmed:languageenglld:pubmed
pubmed-article:3699052pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3699052pubmed:citationSubsetIMlld:pubmed
pubmed-article:3699052pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3699052pubmed:statusMEDLINElld:pubmed
pubmed-article:3699052pubmed:monthFeblld:pubmed
pubmed-article:3699052pubmed:issn0195-668Xlld:pubmed
pubmed-article:3699052pubmed:authorpubmed-author:PalaciosJJlld:pubmed
pubmed-article:3699052pubmed:authorpubmed-author:AlonsoMMlld:pubmed
pubmed-article:3699052pubmed:authorpubmed-author:CosioF GFGlld:pubmed
pubmed-article:3699052pubmed:authorpubmed-author:ArribasFFlld:pubmed
pubmed-article:3699052pubmed:authorpubmed-author:Lopez-GilMMlld:pubmed
pubmed-article:3699052pubmed:issnTypePrintlld:pubmed
pubmed-article:3699052pubmed:volume7lld:pubmed
pubmed-article:3699052pubmed:ownerNLMlld:pubmed
pubmed-article:3699052pubmed:authorsCompleteYlld:pubmed
pubmed-article:3699052pubmed:pagination158-64lld:pubmed
pubmed-article:3699052pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:3699052pubmed:meshHeadingpubmed-meshheading:3699052-...lld:pubmed
pubmed-article:3699052pubmed:meshHeadingpubmed-meshheading:3699052-...lld:pubmed
pubmed-article:3699052pubmed:meshHeadingpubmed-meshheading:3699052-...lld:pubmed
pubmed-article:3699052pubmed:meshHeadingpubmed-meshheading:3699052-...lld:pubmed
pubmed-article:3699052pubmed:meshHeadingpubmed-meshheading:3699052-...lld:pubmed
pubmed-article:3699052pubmed:meshHeadingpubmed-meshheading:3699052-...lld:pubmed
pubmed-article:3699052pubmed:year1986lld:pubmed
pubmed-article:3699052pubmed:articleTitleEffects of intravenous ajmaline on atrial excitability and conduction in man.lld:pubmed
pubmed-article:3699052pubmed:publicationTypeJournal Articlelld:pubmed